180 Wealth Advisors LLC Cuts Stake in Humana Inc. $HUM

Key Points

• 180 Wealth Advisors cut its Humana stake by 83.1% in the second quarter, selling 3,237 shares and retaining 656 shares valued at approximately $260,000.
• Humana reported quarterly earnings of $7.61 per share, beating estimates, while revenue rose 26.2% year over year to $40.89 billion.
• Analyst sentiment remains positive, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $391.87; institutional investors own 92.38% of the company.

180 Wealth Advisors LLC trimmed its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 83.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 656 shares of the insurance provider's stock after selling 3,237 shares during the period. 180 Wealth Advisors LLC's holdings in Humana were worth $260,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in HUM. Montag A & Associates Inc. grew its position in shares of Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock worth $25,000 after buying an additional 94 shares during the last quarter. Fideuram Asset Management Ireland dac purchased a new position in shares of Humana in the 4th quarter valued at approximately $27,000. Reflection Asset Management bought a new stake in shares of Humana during the fourth quarter valued at approximately $29,000. Larson Financial Group LLC boosted its position in shares of Humana by 114.1% during the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider's stock valued at $40,000 after purchasing an additional 81 shares in the last quarter. Finally, CoreCap Advisors LLC grew its stake in Humana by 74.7% in the second quarter. CoreCap Advisors LLC now owns 159 shares of the insurance provider's stock worth $63,000 after purchasing an additional 68 shares during the period. Institutional investors own 92.38% of the company's stock.

Humana Trading Up 4.7%

Humana stock opened at $384.44 on Friday. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $428.88. The company has a market capitalization of $46.16 billion, a price-to-earnings ratio of 36.37, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72. The business's fifty day simple moving average is $377.18 and its two-hundred day simple moving average is $271.65. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, beating the consensus estimate of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to the consensus estimate of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.The company's revenue was up 26.2% on a year-over-year basis. During the same period last year, the company earned $6.27 earnings per share. As a group, equities analysts predict that Humana Inc. will post 9.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Sanford C. Bernstein reissued an "outperform" rating and set a $425.00 price objective on shares of Humana in a research report on Wednesday, June 3rd. Robert W. Baird set a $390.00 target price on shares of Humana in a research report on Thursday, July 30th. Wells Fargo & Company upgraded shares of Humana from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $227.00 to $502.00 in a research note on Monday, July 13th. Morgan Stanley raised shares of Humana from an "underweight" rating to an "equal weight" rating and lifted their price target for the company from $249.00 to $370.00 in a research report on Tuesday. Finally, Oppenheimer reissued an "outperform" rating and set a $405.00 price objective on shares of Humana in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $391.87.

About Humana

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source